All six Zepbound doses become available through LillyDirect self-pay

On July 7, 2025, prescribers were able to begin writing orders for the two highest doses of Zepbound (tirzepatide), 12.5 mg and 15 mg, through Eli Lilly's direct-to-consumer self-pay pharmacy program ^[3]. That completed the full range of six approved Zepbound doses available for cash purchase, from the 2.5 mg starter dose up to 15 mg, with patient shipments of the new doses beginning in early August 2025 ^[3].

The pricing structure has two layers. The 2.5 mg starter dose costs $349 for the first month, and the 5 mg maintenance dose costs $499 per month, with no special conditions attached ^[3][2]. The four highest doses list at higher prices on paper — $599 for 7.5 mg, $699 for 10 mg, $849 for 12.5 mg, and $1,049 for 15 mg — but patients who buy their first fill and then refill within 45 days of their previous delivery pay the same $499 monthly rate under what Lilly calls the Zepbound Self Pay Journey Program ^[3][2]. Miss that 45-day window, and the price reverts to the higher list rate for that dose ^[3].

Lilly describes this self-pay channel as offering a discount of 50 percent or more compared with the list price of competing GLP-1 obesity medicines ^[2]. The company also disclosed that in the second quarter of 2025, roughly 35% of new Zepbound prescriptions were already being filled through this direct-to-consumer channel, before the two highest doses were even added ^[2].

The vials sold through this program are single-dose vials, not the pre-filled KwikPen device, which means patients need separate syringes to draw up and inject their dose ^[2].

Why it matters for patients

For people whose insurance does not cover Zepbound at all, or who are on Medicare or Medicaid — plans that are legally barred from using manufacturer copay cards — this self-pay channel is one of the only ways to get the medicine directly from Lilly at a fixed, published price, regardless of coverage status ^[2][3]. Before July 2025, the higher doses were not part of this arrangement, so patients who needed to titrate up past 5 mg had less price certainty from Lilly's own channel.

The 45-day refill condition is a practical detail with real financial consequences. On the four highest doses, staying on schedule with refills keeps the price at $499 a month; falling outside that window on a 15 mg fill, for example, means paying the full $1,049 list price instead ^[3]. That makes timing of refills, not just the prescription itself, a factor in what patients actually pay.

Because the vials require separate supplies and self-measured injection technique, patients moving from a KwikPen device to this program take on an added step that some may need pharmacist or provider guidance on, though the sources here do not detail specific injection instructions.

What happens next

The self-pay channel expanded further after this July rollout. On Oct. 29, 2025, Lilly and Walmart announced that patients would be able to pick up LillyDirect self-pay vials at nearly 4,600 Walmart pharmacies nationwide, with the option live by mid-November 2025, at the same $349 and $499 price points already in place ^[2]. Lilly said at the time it would continue to look for ways to broaden access to its medicines beyond this initial rollout ^[2].